New antiepileptic medications.
R G
RG
Beran
D000612:4-Aminobutyrate Transaminase / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D000081:Acetamides / Q000627:therapeutic use; D000085:Acetates / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000588:Amines; D000927:Anticonvulsants / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D003509:Cyclohexanecarboxylic Acids; D000077206:Gabapentin; D006801:Humans; D000077213:Lamotrigine; D009557:Nipecotic Acids / Q000627:therapeutic use; D000078308:Tiagabine; D014227:Triazines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D020888:Vigabatrin; D005680:gamma-Aminobutyric Acid / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use
D000081:Acetamides; D000085:Acetates; D000588:Amines; D000927:Anticonvulsants; D003509:Cyclohexanecarboxylic Acids; D009557:Nipecotic Acids; D014227:Triazines; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D000612:4-Aminobutyrate Transaminase; C067553:remacemide; D020888:Vigabatrin; D000077213:Lamotrigine; D000078308:Tiagabine